Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches.

Rood BR, MacDonald TJ.

J Neurooncol. 2005 Dec;75(3):267-72. Review.

PMID:
16195804
2.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
4.

New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.

Brandes AA, Franceschi E.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1129-31. Review. No abstract available.

PMID:
16925479
5.

Development of novel targeted therapies in the treatment of malignant glioma.

Rich JN, Bigner DD.

Nat Rev Drug Discov. 2004 May;3(5):430-46. Review. No abstract available.

PMID:
15136790
6.

Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.

Hargrave D.

Br J Neurosurg. 2009 Aug;23(4):351-63. doi: 10.1080/02688690903158809. Review.

PMID:
19637006
7.

Promising new therapies for malignant gliomas.

Fine HA.

Cancer J. 2007 Nov-Dec;13(6):349-54. Review.

PMID:
18032970
8.

Small molecule inhibitors in children with malignant gliomas.

Herrington B, Kieran MW.

Pediatr Blood Cancer. 2009 Sep;53(3):312-7. doi: 10.1002/pbc.21950. Review.

PMID:
19434732
9.

Altered molecular pathways in gliomas: an overview of clinically relevant issues.

Rao RD, James CD.

Semin Oncol. 2004 Oct;31(5):595-604. Review.

PMID:
15497113
10.

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments.

Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R.

Clin Cancer Res. 2008 Feb 15;14(4):957-60. doi: 10.1158/1078-0432.CCR-07-1810. Review.

11.

Molecularly targeted therapy for pediatric brain tumors.

K E W.

J Neurooncol. 2005 Dec;75(3):335-43. Review.

PMID:
16195796
12.

Cure of Fisher rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays.

Biston MC, Joubert A, Adam JF, Elleaume H, Bohic S, Charvet AM, Estève F, Foray N, Balosso J.

Cancer Res. 2004 Apr 1;64(7):2317-23.

13.

Exposing the defenses of gliomas.

Heimer H.

J Natl Cancer Inst. 1997 Nov 19;89(22):1662. No abstract available.

PMID:
9390533
14.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
15.

Molecularly targeted therapies for malignant gliomas: advances and challenges.

Penas-Prado M, Gilbert MR.

Expert Rev Anticancer Ther. 2007 May;7(5):641-61. Review.

PMID:
17492929
16.

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.

Hanley ML, Elion GB, Colvin OM, Modrich PL, Keir S, Adams DJ, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1998;42(6):479-82.

PMID:
9788574
17.

Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.

Cavaliere R, Newton H.

Expert Opin Pharmacother. 2006 Apr;7(6):749-65. Review.

PMID:
16556090
18.

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

Oncologist. 2006 Feb;11(2):165-80. Review.

19.

Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?

Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME.

Mol Cancer Res. 2009 Jul;7(7):1000-12. doi: 10.1158/1541-7786.MCR-08-0479. Epub 2009 Jul 7. Review.

20.

Therapy for recurrent malignant glioma in adults.

Mrugala MM, Kesari S, Ramakrishna N, Wen PY.

Expert Rev Anticancer Ther. 2004 Oct;4(5):759-82. Review.

PMID:
15485312

Supplemental Content

Support Center